Maravai LifeSciences appoints Bernd Brust as CEO, succeeds Trey Martin.

• Maravai LifeSciences appoints Bernd Brust as CEO and board member. • Brust succeeds Trey Martin III in the roles. • Brust has 30 years of experience in the life sciences industry. • He has a proven track record of transforming businesses into profitable companies. • Brust's appointment reflects Maravai's commitment to accelerating innovation and financial performance.

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) has appointed Bernd Brust as the new Chief Executive Officer (CEO) and a member of its Board of Directors, effective immediately. Mr. Brust succeeds William “Trey” Martin III in these roles [1].

Bernd Brust brings over 30 years of leadership experience in the life sciences industry, with a proven track record of transforming businesses into profitable, revenue-growing companies with global product and service portfolios [1]. His appointment reflects Maravai’s commitment to accelerating innovation and financial performance [1].

Mr. Brust’s customer-centric approach and background in transforming scientific organizations align strongly with Maravai’s mission to advance scientific discovery and innovation [1]. His leadership reinforces Maravai’s commitment to delivering high-impact solutions to researchers and biotech innovators around the world [1].

“I am honored to lead Maravai, a company perfectly positioned to serve the growing biologics and genomic medicine markets,” said Bernd Brust. “Maravai is grounded in innovation and powered by deep scientific excellence and passion for its customers. I look forward to working closely with the Board, team members, and customers to help advance breakthroughs from discovery to delivery” [1].

The appointment of Bernd Brust comes as Maravai LifeSciences continues to expand its market leadership in mRNA, bioprocess impurity detection and analytics, and enhance manufacturing capabilities [1]. The company remains well positioned for long-term success, backed by a strong financial foundation and a growing portfolio of innovative products [1].

Maravai LifeSciences is neither reaffirming nor withdrawing its previously issued full-year 2025 financial guidance at this time. The company will revisit its outlook during the second-quarter earnings call in August, following a comprehensive assessment of the business by newly appointed CEO Mr. Brust [1].

References:
[1] https://www.marketscreener.com/quote/stock/MARAVAI-LIFESCIENCES-HOLD-115395180/news/Maravai-LifeSciences-Appoints-Bernd-Brust-as-Chief-Executive-Officer-and-Member-of-its-Board-of-Dire-50191479/